A 2-year Observational Study to Evaluate Safety of Seretide 50/500μg Twice Daily Administered by DISKUS, in Patients With COPD
Phase of Trial: Phase IV
Latest Information Update: 17 Jan 2014
At a glance
- Drugs Salmeterol/fluticasone propionate (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions
- Sponsors GlaxoSmithKline
- 07 Jun 2017 Biomarkers information updated
- 17 Jan 2014 Status changed from active, no longer recruiting to completed according to ClinicalTrials.gov record.
- 16 May 2008 New trial record.